Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 29 Aug 2025
Research led by the Indiana University School of Medicine and the University of Florida reports an association between taking GLP-1 receptor agonists and lower overall cancer risk in adults with obesity or overweight, with ...
Read Full NewsThe World Health Organization on Friday urged governments to do more to control the sale of nicotine pouches, warning that the highly addictive products were being...
Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.
The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.
1.
Interleukin-6 may boost prediction of obesity-related cancers
2.
Breast cancer screening in women's 40s can save lives, study says
3.
Higher levels of HIF2α found to slow down aggressive childhood cancer
4.
How scientists are hacking bacteria to treat cancer, self-destruct, then vanish without a trace
5.
TULSA Is Effective in Long-Term Prostate Cancer Control.
1.
A New Perspective on Spherocytosis: Uncovering Innovative Treatments
2.
Understanding QSOFA: A Vital Tool for Recognizing Sepsis
3.
Mastering Surgical Oncology: Education, Certification, Trials, and Therapy Insights
4.
Stomach Cancer: Uncovering the Subtle Signs and Symptoms
5.
Unlocking the Secrets of Squamous Cell Carcinoma: New Hope for Patients
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
2.
Navigating the Complexities of Ph Negative ALL - Part XI
3.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
4.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma - Part V
5.
Revolutionizing Treatment of ALK Rearranged NSCLC with Lorlatinib - Part V
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge